Lead Sponsor

R-Pharm

Collaborators

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) ≥ 50
•Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer
•Prior chemotherapy is permitted with no limit on the number of prior regimens
•Two weeks or more have elapsed since last chemotherapy or radiation treatment
•Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2
•Is female, ≥ 18 yrs of age
•Protocol defined appropriate laboratory values
•Negative pregnancy test within 7 calendar days prior to registration
•Has signed a patient informed consent

•Had prior treatment with ixabepilone or other epothilones
•Has HER2+ disease
•Has a known, prior, severe (National Cancer Institute Common Terminology Criteria Adverse Events \[NCI CTCAE\] Grade 3-4) history of hypersensitivity reaction to a drug formulated in Cremophor ® EL (polyoxyethylated castor oil)
•Is receiving concurrent immunotherapy, hormonal therapy or radiation therapy
•Is receiving concurrent investigational therapy or has received such therapy within the past 30 days
•Has peripheral neuropathy \> Grade 1
•Has evidence of central nervous system (CNS) involvement requiring radiation or steroid treatment. Participants with stable brain metastases who are off steroids at least 2 weeks are eligible
•Is pregnant or breast feeding

Related studies

NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer

NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer

NCT07085767 · Breast Cancer, Locally Advanced Breast Cancer, and more

NCT05660083 · HER2-negative Breast Cancer, Metastatic Breast Cancer, and more

NCT07354022 · Locally Advanced or Metastatic Breast Cancer

Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer